Arkolith/Insider Trading/BTAI/Form 4

Steinhart Richard I

Chief Financial OfficerBioXcel Therapeutics, Inc. (BTAI) · full profile →Form 4 · filed Dec 15, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 15, 2025Option exercise(M)35——7K
Dec 14, 2025Option exercise(M)33——7K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 15, 2025Option exercise(M)35—$0282
Dec 14, 2025Option exercise(M)33—$0130

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-121303) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML